Senhwa Biosciences' CX-5461 Teams Up with Global PD-1 Leaders to Enter the Immunotherapy Arena, Targeting Multi-Billion Dollar Global Market

TAIPEI and SAN DIEGO, Sept. 16, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492, "Senhwa") today announced its official entry into the fast-growing global immuno-oncology market. The Company's novel investigational drug Pidnarulex (CX-5461) will be evaluated in combination with...